From the viewpoint of neurotransmitters and neurotransmission for the brain, cerebral, cerebellar, hypothalamus, and hippocampus lesions, and cytoprotection as innate background for the interconnected pleiotropic beneficial effect, there is growing evidence that BPC 157 therapy can counteract the occlusion/occlusion-like syndromes [40,41,42,43,47,48,49,50,51,52,53,54,55,56]
Refrigeration slows this conversion, maintaining effective preservative concentration closer to the 0.9% starting level through the 28-day window
BMC Cancer 21 , 28 (2021)
The combination of BPC-157 plus TB-500, often called the Wolverine Stack, adds a systemic recovery component to BPC-157s local action